Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19

Oisín Kavanagh, Anne Marie Healy, Francis Dayton, Shane Robinson, Niall J. O'Reilly, Brian Mahoney, Aisling Arthur, Gavin Walker, John P. Farragher

Research output: Contribution to journalLetterpeer-review

Abstract

Current formulations and dose regimens of hydroxychloroquine (HCQ) put patients at risk of harm. An analysis of clinical trials registered on ClinicalTrials.gov revealed that this may continue as many studies combine HCQ with agents that prolong the QT interval. Further, almost all of the trials registered do not consider dosage adjustment in the elderly, a patient population most likely to require HCQ treatment. Here we describe an inhaled formulation of HCQ which has passed safety studies in clinical trials for the treatment of asthma and discuss how this approach may reduce side-effects and improve efficacy. As this simple formulation progressed to phase II studies, safety data can be used to immediately enable phase II trials in COVID-19.

Original languageEnglish
Article number110110
JournalMedical Hypotheses
Volume143
DOIs
Publication statusPublished - Oct 2020

Fingerprint

Dive into the research topics of 'Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19'. Together they form a unique fingerprint.

Cite this